The healthcare system waits for physiologic failure then scrambles to compensate for the damage (heart failure/diabetes). Treacherous “wellness” waters harbor bio-hacks & unstudied therapeutics. Arc-1 works with people in their 40s who want to be impressive in their 60s (+). We start by analyzing: • where your health is right now • where you want your body and mind to take you(future-self): function, activity, & performance The goal is “second-half strategy” as we navigate through this life.
Aptar Digital Health
Aptar Digital Health creates end-to-end solutions to enhance patient experiences every day, leveraging a holistic ecosystem of digital interventions. Amplified by an industry-leading portfolio of products and solutions, Aptar Digital Health’s offering combines mobile and web apps, Software-as-Medical-Device, connected drug delivery systems, advanced data analysis services, and patient onboarding and training solutions to actively empower patients and create a positive treatment journey.
Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across many serious diseases. | We are delivering meaningful advances for patients with serious diseases who previously had few, or no, approved treatment options. Our medicines are making a difference for patients with: -Geographic atrophy (GA) – a leading cause of blindness -C3 glomerulopathy (C3G) and primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) – two severe, rare kidney diseases -Paroxysmal nocturnal hemoglobinuria (PNH) – a rare, life-threatening blood disorder. And we believe we have only begun to unlock the full potential of targeting C3 for patients. With perseverance and passion, we have advanced two C3-targeting medicines from discovery through development and commercialization. Today, we are leveraging our complement expertise to develop new treatments for patients living with serious diseases.
ANI Pharmaceuticals
ANI Pharmaceuticals is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company’s Rare Disease business markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology. For additional information, visit www.anipharmaceuticals.com. | ANI Pharmaceuticals is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products. We are focused on building a successful branded franchise, strengthening our generics business and established brands, and leveraging our North American manufacturing capabilities. Additional information, www.anipharmaceuticals.com. | ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), headquartered in Baudette, MN is an integrated specialty generic pharmaceutical company with a commercial portfolio of over 50 generics and 11 brand products. ANI is focused on delivering value through partnerships, strategic alliances, acquisitions, re-commercialization of previously-approved products, as well as traditional development.
Animal Health International, Inc.
Animal Health International is a full-service distributor committed to helping beef producers increase production and improve efficiencies. Through our innovative technologies, expert knowledge, expansive product portfolio and fast, customizable delivery options, we help customers manage a sustainable and profitable operation and keep the animals in their care healthy and safe.
Anaplan
Anaplan delivers real-time, intelligent connected planning solutions that power hundreds of the world’s most sophisticated retailers, CPG companies and consumer supply chains. Built on a secure platform that both business and IT teams love, Anaplan enables organizations to connect data, processes, and teams across the entire merchandise lifecycle. From merchandise financial planning to allocation, replenishment, and assortment planning, Anaplan’s integrated approach drives collaboration, agility, and smarter decision-making at scale for faster, better results. Now, with best-in-class supply chain and retail applications and out-of-the-box AI-driven analytics, Anaplan is accelerating time to value and unlocking new levels of operational excellence for even the most complex retail organizations. Retailers benefit from real-time insights, scenario modeling, and dynamic forecasting, allowing them to adapt swiftly to market changes and align inventory and financial strategies for maximum impact. Stop by our booth or join us for the conversation on Monday to learn why the biggest names in retail are choosing Anaplan. | Anaplan is a transformative way to see, plan, and run your business. Using our proprietary Hyperblock™ technology, Anaplan lets you contextualize real-time performance, and forecast future outcomes for faster, confident decisions. Anaplan enables connected strategy and planning across your enterprise to move your business forward. Based in San Francisco, Anaplan has over 200 partners and more than 2,000 customers worldwide, including many global retailers. To learn more, visit Anaplan.com | Anaplan delivers real-time, intelligent connected planning solutions that power hundreds of the world’s most sophisticated retailers, CPG companies and consumer supply chains. Built on a secure platform that both business and IT teams love, Anaplan enables organizations to connect data, processes, and teams across the entire merchandise lifecycle. From merchandise financial planning to allocation, replenishment, and assortment planning, Anaplan’s integrated approach drives collaboration, agility, and smarter decision-making at scale for faster, better results.Now, with best-in-class supply chain and retail applications and out-of-the-box AI-driven analytics, Anaplan is accelerating time to value and unlocking new levels of operational excellence for even the most complex retail organizations. Retailers benefit from real-time insights, scenario modeling, and dynamic forecasting, allowing them to adapt swiftly to market changes and align inventory and financial strategies for maximum impact. | Anaplan is the only scenario planning and analysis platform designed to optimize decision-making in today’s complex business environment so that enterprises can outpace their competition and the market. By building connections and collaboration across organizational silos, our platform intelligently surfaces key insights — so businesses can make the right decisions, right now. More than 2,500 of the world’s best brands continually optimize their decision- making by planning with Anaplan.
Amgen
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2025, Amgen was named to Fortune’s list of the World’s Most Admired Companies. | Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. | Biotech | x | Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. | Our mission is to serve patients. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.
Alnylam
Alnylam has led the translation of RNA interference into a new class of approved and investigational medicines for transthyretin amyloidosis (TTR), rare, cardiovascular, metabolic, neurologic and other diseases. Learn more: www.alnylam.com. | Since its founding, Alnylam has led the translation of RNA interference (RNAi) into a new class of approved and investigational medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics are a clinically validated approach for the treatment of rare diseases with unmet medical need and prevalent diseases. Alnylam is headquartered in Cambridge, MA. For more information, please visit www.alnylam.com.
Almatica
Almatica is dedicated to developing affordable quality medications to treat mental health conditions. As a privately held specialty US pharmaceuticals company, we are driven by our desire to fulfill unmet patient needs and help improve quality of life by developing innovative medications that treat neurologic and psychiatric diseases.
Alkermes
Alkermes applies its deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. A fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we seek to make a meaningful difference in the way people manage their diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized. Visit www.alkermes.com to learn more. | Alkermes leverages its deep neuroscience expertise to develop medicines designed to help people living with complex psychiatric and neurological disorders. A fully-integrated, global biopharmaceutical company with locations in the U.S. and Ireland, we seek to make a meaningful difference in the way people manage their diseases. Learn more: www.alkermes.com.